Voyager Therapeutics Inc. (VYGR)
NASDAQ: VYGRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VYGR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $95.21M
- EPS (TTM)
- -$1.74
- Dividend yield
- None
- 52-week range
- 1.48 – 5.48
- Day range
- 1.51 – 1.65
- Volume / Avg
- 639.24K / 770.24K
- Beta
- —
- Shares outstanding
- 62.23M
52-week range
VYGR stock today
Voyager Therapeutics (VYGR) closed at $1.53 on Nov 20, down 4.97% (-$0.08), versus the S&P 500's 3.70% decline. At this level, VYGR sits near the bottom of its 52-week range of $1.48 to $5.48: 72.1% below the high, set on Mar 11, 2026 and 3.4% above the low. VYGR is down 61.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.4%.
Voyager Therapeutics has posted a net loss over the last twelve months (EPS of -$1.74), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Voyager Therapeutics
Company profileVoyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
- Headquarters
- Lexington, MA
- Employees
- 141
- IPO year
- 2015
- Website
- voyagertherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Voyager Therapeutics generated $40.4 million in revenue, down 49.5% from fiscal 2024, its first annual decline since 2024. Voyager Therapeutics reported a net loss of $119.7 million, compared with a loss of $65.0 million a year earlier. Operating margin was -326.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $40.37M | $80.00M | $250.01M | $40.91M | $37.41M |
| Growth | -49.53% | -68.00% | +511.16% | +9.33% | -78.14% |
| Net income | $-119.72M | $-65.00M | $132.33M | $-46.41M | $-71.20M |
| EPS (diluted) | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$14.22+829.41%
- Strong buy 0
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.40 vs $-0.41
- Surprise
- +2.44%
VYGR news
All VYGR news- Voyager Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Pipeline UpdatesNasdaq
- Voyager Therapeutics Reports Third Quarter 2026 Financial Results and $132 Million Cash PositionNasdaq
- Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue EstimatesNasdaqVYGR, ROIV
- Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026GlobeNewswire
- Voyager Appoints Robin Swartz As President, CEO Transition Expected In Q1 2027; Stock DownNasdaqVYGR, HEI.A
- Voyager Announces CEO Succession Plan, Appoints Robin Swartz PresidentGlobeNewswire
Voyager Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OTLKOutlook Therapeutics Inc. | 0.39 | -2.74% | $94.94M | vs VYGR |
| IPHAInnate Pharma S.A. ADS | 0.8634 | -8.14% | $96.44M | vs VYGR |
| MOLNMolecular Partners AG ADR | 2.53 | -5.25% | $96.80M | vs VYGR |
| LENZLENZ Therapeutics Inc. | 2.97 | -11.23% | $93.16M | vs VYGR |
| ZURAZura Bio Limited Class A | 0.9305 | -2.30% | $89.63M | vs VYGR |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs VYGR |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs VYGR |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs VYGR |
Indexes, lists and sector
Voyager Therapeutics stock FAQ
What is Voyager Therapeutics's stock price today?
VYGR last traded at $1.53 as of Nov 20, 4:00 PM EST, down 4.97% on the day. Prices are delayed at least 15 minutes.
Who is Voyager Therapeutics's CEO?
Dr. Alfred W. Sandrock Jr., M.D., Ph.D. is the chief executive officer of Voyager Therapeutics Inc., which has about 141 employees.
What is the VYGR 52-week high?
The 52-week high for VYGR is $5.48 and the 52-week low is $1.48. The stock is currently 72.1% below its high.